Table 4 Treatment-related adverse events in the two groups
AEs | anlotinib monotherapy (n = 30) | anlotinib combination (n = 52) | P value |
|---|---|---|---|
Systemic disease (fatigue) | 2 | 3 | 1.000 |
Cardiovascular diseases (hypertension) | 2 | 3 | 1.000 |
Bleeding (hemoptysis, gum bleeding, nasal mucous membrane bleeding) | 2 | 6 | 0.742 |
Gastrointestinal disease (abdominal pain) | 1 | 1 | 1.000 |
Diseases of the skin and subcutaneous tissue (hand and foot syndrome, rash) | 0 | 6 | 0.136 |
Respiratory disease (cough, lung infection) | 2 | 2 | 0.969 |
Diseases of the blood system (decreased platelet count, deficiency of granules) | 0 | 4 | 0.305 |
Endocrine system (hypothyroidism or hyperthyroidism) | 1 | 2 | 1.000 |